期刊文献+

阿仑膦酸钠引发食管炎的探讨

Relationship clinical research between esophagitis and alendronate treatment on postmenopausal osteoporosis
下载PDF
导出
摘要 目的探讨绝经后妇女口服阿仑膦酸钠引发食管炎对患者耐受性的影响。方法采用临床配对平行对照研究。计划入组病例60例,评估后,入选患者均经胃镜检查,经配对分入试验组或对照组。试验治疗疗程为12个月,在治疗前、6个月末和12个月末对阿仑膦酸钠引发食管炎的安全性进行评估。结果治疗后骨密度明显上升,阿仑膦酸钠组与碳酸钙组比较差异有统计学意义(P<0.01)。食管炎的发生率两组差异无统计学意义(碳酸钙组:14.17%、阿仑膦酸钠组:15.83%)。结论阿仑膦酸钠在增加骨密度、减少骨折的同时,并无增加食管炎甚至食管溃疡的风险。 Objective To investigate incidence of esophagitis and other side effect of alendronate in the treatment on postmenopausal osteoporosis. Methods The clinical paired parallel controlled study included 60 cases which were treatment divided into group and control group after diagnosed by gastroscopy, there was significant differ- ence in age, body weight, bone mineral density and the endoscopic manifestations in two groups. The study duration was 12 months. We assessed the esophagitis induced by alendronate at three point (prion to treatment, 6 months and 12 months ). Results After alendronate treatment, the bone mineral density increased significantly (P 〈 0.01 ). The inci- dence of was not significantly different esophagitis in two groups (calcium carbonate group: 14. 17%, alendronate group : 15.83% ). Conclusion Alendronate increase bone mineral density without significant adverse reactions.
出处 《中国临床保健杂志》 CAS 2013年第2期131-132,I0001,共3页 Chinese Journal of Clinical Healthcare
基金 陕西省科技厅社发公关项目(2007K15-05)
关键词 骨质疏松 绝经后 食管炎 二磷酸盐类 碳酸钙 Osteoporosis, postmenopausal Esophagitis Diphosphonates Calcium carbonate
  • 相关文献

参考文献6

二级参考文献50

  • 1刘忠厚,杨定焯,朱汉民,王洪复,张柳,唐海,赵燕玲.中国人原发性骨质疏松症诊断标准(试行)[J].中国骨质疏松杂志,1999,5(1):1-3. 被引量:244
  • 2徐志英,梁九根,蒋宁一,卢献平,刘生,刘幸光,陈少雄,伦倚云.围绝经期及绝经后妇女骨量变化规律的初步分析[J].中国骨质疏松杂志,2006,12(4):378-380. 被引量:27
  • 3帆继援 郑淑蓉 梁奕诠 等.利塞膦酸钠对绝经后骨质疏松郑妇女骨转换标志物的影响.骨质疏松和骨矿物盐疾病基础与临床,2003,:139-141.
  • 4Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of Alendronate: 7-year treaunent of postmenopausal osteoporotic women[J]. J Clin Endocrinol Metab, 2000,85:3109- 3115.
  • 5Hernandez CJ, Boaupre GS, Marcus R, et al. A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during Alendronate treaunentE[J]. Bone, 2001,29:511- 516.
  • 6Liberman UA, Weiss SR, Broll J, et al . Effect of oral Alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis[J]. N Engl J Med, 1995,333:1437- 1443.
  • 7Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of Alendronate on fracture-related healthcare utilization and costs:the fracture intervention trial[J]. Osteoporos Int, 2001,12:654 - 660.
  • 8Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of Alendronate on risk of fracture in women with existing vertebral fxacture[J]. Lancet, 1996,348:1535 - 1541.
  • 9Watts NB, Jenkins DK, Visor JM, etal. Comparison of bone and total Alakine Phosphatase and bone mineral density in postmenopausal osteoporotic women treated with Alendronate [J].Osteoporos Int, 2001,12:279 - 288.
  • 10Bauer DC, BlackD, Ensrud K, etal. Upper gastrointestinal tract safety profile of Alendronate : The fracture intervention trial[J]. Arch Intern Med, 2000,160:517- 525.

共引文献1913

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部